Amgen 2012 Annual Report Download - page 63

Download and view the complete annual report

Please find page 63 of the 2012 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 150

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150

56
We believe that our facilities are suitable for their intended use and, in conjunction with our third-party contracting
manufacturing agreements, provide adequate capacity. We also believe that our existing facilities, our third-party contract
manufacturing agreements and our anticipated additions are sufficient to meet our expected needs. See Item 1A. Risk Factors — We
perform a substantial amount of our commercial manufacturing activities at our Puerto Rico manufacturing facility and a substantial
amount of our clinical manufacturing activities at our Thousand Oaks, California, manufacturing facility; if significant natural
disasters or production failures occur at the Puerto Rico facility, we may not be able to supply these products or, at the Thousand
Oaks facility, we may not be able to continue our clinical trials, — We rely on third-party suppliers for certain of our raw materials,
medical devices and components and — Manufacturing difficulties, disruptions or delays could limit supply of our products and
limit our product sales.
Item 3. LEGAL PROCEEDINGS
Certain of the legal proceedings in which we are involved are discussed in Note 18, Contingencies and commitments, to
our Consolidated Financial Statements in this Annual Report on Form 10-K and are hereby incorporated by reference.
Item 4. MINE SAFETY DISCLOSURES
Not applicable.
PART II
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES
Common stock
Our common stock trades on The NASDAQ Global Select Market under the symbol AMGN. As of February 19, 2013, there
were approximately 8,466 holders of record of our common stock.
The following table sets forth, for the periods indicated, the range of high and low quarterly closing sales prices of the
common stock as quoted on The NASDAQ Global Select Market:
Year ended December 31, 2012 High Low
Fourth quarter $ 90.17 $ 84.00
Third quarter 84.81 73.85
Second quarter 73.02 65.59
First quarter 69.84 63.76
Year ended December 31, 2011
Fourth quarter $ 64.74 $ 53.90
Third quarter 58.28 48.27
Second quarter 61.17 53.08
First quarter 57.31 50.95